Benzoxazinone-containing 3,5-dimethylisoxazole derivatives as BET bromodomain inhibitors for treatment of castration-resistant prostate cancer | |
Xue, Xiaoqian[1,2,3]; Zhang, Yan[1,2,3]; Wang, Chao[1,2]; Zhang, Maofeng[1,2,3]; Xiang, Qiuping[1,2,3]; Wang, Junjian[4]; Wang, Anhui[5,6]; Li, Chenchang[1,2,7]; Zhang, Cheng[1,2,7]; Zou, Lingjiao[1,2,3] | |
2018 | |
卷号 | 152页码:542 |
URL标识 | 查看原文 |
内容类型 | 期刊论文 |
URI标识 | http://www.corc.org.cn/handle/1471x/4768796 |
专题 | 暨南大学 |
作者单位 | 1.[1]Chinese Acad Sci, Guangzhou Inst Biomed & Hlth, Joint Sch Life Sci, Guangdong Prov Key Lab Biocomp, Guangzhou 510530, Guangdong, Peoples R China 2.[2]Guangzhou Med Univ, Guangzhou 510530, Guangdong, Peoples R China 3.[3]Univ Chinese Acad Sci, 19 Yuquan Rd, Beijing 100049, Peoples R China 4.[4]Univ Calif Davis, Sch Med, Dept Biochem & Mol Med, Sacramento, CA 95817 USA 5.[5]Dalian Univ Technol, Sch Chem, State Key Lab Fine Chem, Dalian 116023, Peoples R China 6.[6]Chinese Acad Sci, Dalian Inst Chem Phys, State Key Lab Mol React Dynam, Lab Mol Modeling & Design, Dalian 116023, Peoples R China 7.[7]Jilin Univ, Sch Pharmaceut Sci, 1266 Fujin Rd, Changchun 130021, Jilin, Peoples R China 8.[8]Jinan Univ, Sch Pharm, 601 Huangpu Ave West, Guangzhou 510632, Guangdong, Peoples R China |
推荐引用方式 GB/T 7714 | Xue, Xiaoqian[1,2,3],Zhang, Yan[1,2,3],Wang, Chao[1,2],et al. Benzoxazinone-containing 3,5-dimethylisoxazole derivatives as BET bromodomain inhibitors for treatment of castration-resistant prostate cancer[J],2018,152:542. |
APA | Xue, Xiaoqian[1,2,3].,Zhang, Yan[1,2,3].,Wang, Chao[1,2].,Zhang, Maofeng[1,2,3].,Xiang, Qiuping[1,2,3].,...&Xu, Yong[1,2].(2018).Benzoxazinone-containing 3,5-dimethylisoxazole derivatives as BET bromodomain inhibitors for treatment of castration-resistant prostate cancer.,152,542. |
MLA | Xue, Xiaoqian[1,2,3],et al."Benzoxazinone-containing 3,5-dimethylisoxazole derivatives as BET bromodomain inhibitors for treatment of castration-resistant prostate cancer".152(2018):542. |
个性服务 |
查看访问统计 |
相关权益政策 |
暂无数据 |
收藏/分享 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论